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Abstract
The aim was to analyze the characteristics and predictors of unfavorable outcomes in solid
organ transplant recipients (SOTRs) with COVID-19. We conducted a prospective observa-
tional cohort study of 210 consecutive SOTRs hospitalized with COVID-19 in 12 Spanish
centers from 21 February to 6 May 2020. Data pertaining to demographics, chronic underly-
ing diseases, transplantation features, clinical, therapeutics, and complications were col-
lected. The primary endpoint was a composite of intensive care unit (ICU) admission and/or
death. Logistic regression analyses were performed to identify the factors associated with
these unfavorable outcomes. Males accounted for 148 (70.5%) patients, the median age
was 63 years, and 189 (90.0%) patients had pneumonia. Common symptoms were fever,
PLOS ONE







Citation: Salto-Alejandre S, Jiménez-Jorge S, Sabé
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cough, gastrointestinal disturbances, and dyspnea. The most used antiviral or host-targeted
therapies included hydroxychloroquine 193/200 (96.5%), lopinavir/ritonavir 91/200 (45.5%),
and tocilizumab 49/200 (24.5%). Thirty-seven (17.6%) patients required ICU admission, 12
(5.7%) suffered graft dysfunction, and 45 (21.4%) died. A shorter interval between trans-
plantation and COVID-19 diagnosis had a negative impact on clinical prognosis. Four base-
line features were identified as independent predictors of intensive care need or death:
advanced age, high respiratory rate, lymphopenia, and elevated level of lactate dehydroge-
nase. In summary, this study presents comprehensive information on characteristics and
complications of COVID-19 in hospitalized SOTRs and provides indicators available upon
hospital admission for the identification of SOTRs at risk of critical disease or death, under-
lining the need for stringent preventative measures in the early post-transplant period.
Introduction
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
causative agent of coronavirus disease 2019 (COVID-19), emerged in China [1]. It spread
globally, becoming a public health emergency and a pandemic of historic dimensions [2].
Spain has been one of the most affected countries in the world in terms of absolute number of
diagnosed cases and deaths per capita [3], causing a dramatic decline in donations and trans-
plantation procedures per day, with mean numbers dropping from 7.2 to 1.2 and 16.1 to 2.1,
respectively [4].
The clinical spectrum of COVID-19 ranges from asymptomatic disease to pneumonia, life-
threatening complications, and ultimately death [5–7]. Risk factors for severe disease in the
general population include older age and comorbidities [8], but the impact of chronic immu-
nosuppression related to transplantation on COVID-19 is not well known. Despite widespread
concern that COVID-19 clinical phenotypes may be more severe among solid organ transplant
recipients (SOTRs) due to a poorer inflammatory response and greater organ injury, data on
this population are limited to a few case series and generally small retrospective cohorts [9–
25].
As hospitals around the world prepare for a rising and maintained incidence of COVID-19,
important questions on the natural history of the disease, susceptibility of SOTRs, severity risk
factors, and transplant specific management of antivirals and immunosuppressants remain
unanswered [26]. This multicenter study aimed to shed light on said matters, presenting the
clinical characteristics, treatments, and predictors of unfavorable outcomes (intensive care




We conducted a nationwide prospective observational cohort study (S1 Table for STROBE
checklist) within the Spanish Network for Research in Infectious Diseases (REIPI) and the
Group for the Study of Infection in Transplantation and the Immunocompromised Host
(GESITRA-IC). Investigators from the 12 participating centers from different regions of Spain
were asked to include all consecutive SOTR adults hospitalized with confirmed COVID-19 by
real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 in respiratory samples,
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from 21 February to 6 May 2020. The baseline was the date of hospital admission, and the fol-
low-up censoring date was 6 June 6 2020. The study protocol was approved by the Ethics Com-
mittee of Virgen del Rocı́o and Virgen Macarena University Hospitals (C.I. 0842-N-20), as
well as by the proper institutional review board of each participating center (individual codes
are listed in the Supporting Information), and complied with the Helsinki Declaration. Writ-
ten informed consent was established as a mandatory requirement for all patients.
Data collection
The data source was the electronic medical record system. Anonymized data were collected
using an electronic Case Report Form (eCRF) and added to a database specifically designed
for this study built using Research Electronic Data Capture (REDCap) tools [27]. The regis-
tered variables included demographics, comorbidities, transplant type and date, signs and
symptoms at admission, baseline laboratory tests and chest X-ray findings, complications dur-
ing hospitalization, management of immunosuppression, therapeutics with purported activity
against COVID-19, adjunctive strategies to modulate the host inflammatory response, and
clinical outcomes.
Event of interest
The clinical outcomes of patients after 30 days follow-up were categorized into favorable (full
recovery and discharged or stable clinical condition) and unfavorable (admission to ICU or
death). For patients who were discharged and subsequently readmitted during the study
period, only the first hospital admission episode was considered for purposes of analysis. The
primary endpoint was the occurrence of an unfavorable outcome, that is, a composite of ICU
admission and/or death.
Statistical approach
A descriptive analysis of all obtained data was performed. Categorical variables were presented
as n (%) and continuous variable as mean (standard deviation (SD)) or median (interquartile
range (IQR)) according to the normality of the distribution. We used the χ2-test, Yates’ Cor-
rection for Continuity, Student’s t-test, or Welch’s t-test to compare between-group differ-
ences, as appropriate.
To examine factors associated with unfavorable clinical outcomes, quantitative variables
were dichotomized based on normal ranges and in the cut-offs associated with unfavorable
outcomes in the general population [28], after addressing their effects as continuous. Univari-
able and multivariable logistic regression analyses were performed, and bivariate relationships
between all predictors were thoroughly explored to account for potential confounding, collin-
ear, and interaction effects.
For obtaining a reduced set of variables from the predictors identified in the univariable
analysis, a multivariable analysis was carried out using three criteria to achieve the most accu-
rate model: relevance to clinical situation, statistical significance (P< 0.10), and adequate
number of events to allow for meaningful analysis. An automated backward stepwise selection
was used for exclusion of variables utilizing a 5% probability threshold [29]. Gender, presence
of comorbidities, lung transplantation, and immunosuppression regimens with high doses of
mofetil mycophenolate (�1080 mg/day) or prednisone (�20 mg/day) appeared as possible
confounders and were therefore included in the final model for adjustment. White blood cell
count and oxygen saturation were excluded to prevent collinearity, since neutrophil count and
respiratory rate were part of the model. We found no clinically meaningful interactions among
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the potential ones examined (sex and inflammatory markers, age, and immunity response),
which were not therefore included in the model as a term.
Although there are no defined well-validated measures of immunosuppression intensity,
we performed a univariable analysis to specifically assess the following as possible surrogates
in accordance with prior studies: earlier time post-transplant, thoracic (lung or heart) com-
pared to non-thoracic graft, receipt of augmented mofetil mycophenolate and prednisone dos-
ages, and higher number of baseline maintenance immunosuppressive agents [12, 30, 31]. To
further ascertain the impact of a shorter interval between transplantation and COVID-19 diag-
nosis, as well as the type of transplant received, on unfavorable outcome, we carried out a sen-
sitivity analysis where the roles of the dependent and independent variables were inverted.
Analyses were done using the software package SPSS (Version 26.0. Armonk, NY: IBM
Corp.). All P-values were derived from two-tailed tests, and those <0.05 were considered sta-
tistically significant.
Results
Patients’ characteristics and clinical presentation
The cohort included 210 hospitalized adult SOTRs in which SARS-CoV-2 was detected by
RT-PCR from nasopharyngeal swabs (97.6%), sputum (1.9%), and endotracheal aspirate
(0.5%). One hundred eight (51.4%) patients were kidney recipients, 50 (23.8%) were liver, 33
(15.7%) were heart, 15 (7.1%) were lung, and 4 (1.9%) were kidney–pancreas recipients. The
median time from transplant to COVID-19 diagnosis was 6.6 (IQR 2.8–13.1) years. Six (2.9%)
patients were in the first month posttransplant, 12 (5.7%) in the first three months, 18 (8.6%)
in the first six months, and 29 (13.8%) in the first-year posttransplant. The median admission
date was 25 March 2020, with little variability between centers (IQR from March 18 to April
1). Median length of hospitalization was 13 (IQR 7–19) days. Sixty-three (30.0%) patients
experienced an unfavorable outcome at final follow-up, and 147 (70.0%) patients had a favor-
able course of the disease. Patients’ characteristics, of the total cohort and categorized by clini-
cal outcome, are shown in Table 1.
In brief, males accounted for 148 (70.5%) patients, the median age was 63 (IQR 51–71)
years, and 28.6% were�70 years old. The age distribution of patients stratified by clinical out-
come is shown in Fig 1. Age�70 years (P = 0.001) and shorter time from transplantation
(P = 0.048) were associated with a poor clinical result, unlike other baseline demographics
including sex or type of graft. At least one comorbidity was present in 85.2% patients, the most
common being chronic kidney disease (35.2%), followed by diabetes mellitus (33.3%) and
chronic cardiopathy (25.7%), all of which were more prevalent in the unfavorable outcome
group. The median duration of symptoms before hospitalization was six (IQR 3–10) days, and
the most common symptoms were fever (66.7%), cough (65.2%), gastrointestinal disturbances
(41.0%), and dyspnea (38.6%). Dyspnea upon presentation was associated with unfavorable
outcomes (P< 0.001), while other initial symptoms were analogous between groups. Similarly,
there were no differences among baseline immunosuppression, where triple therapy was the
preferred maintenance regimen, and the subsequent clinical evolution of COVID-19.
Chest X-ray, hemodynamic, and laboratory findings
One hundred eighty-nine (90.0%) SOTRs had abnormal chest X-ray images: 85.7% within the
favorable and 100% in the unfavorable outcome groups (P = 0.002). Patients with unfavorable
clinical outcomes had higher respiratory rate (P< 0.001) and lower capillary oxygen satura-
tion (P = 0.03) on initial presentation than those with a favorable disease course. We also
found between-group differences regarding the baseline laboratory values. In terms of blood
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Table 1. Demographics, comorbidities, clinical data, and baseline immunosuppression in all patients and by clinical outcome at final follow-up.
All (n = 210) Favorable Outcome (n = 147) Unfavorable Outcome (n = 63) P-value
Age in years, mean (SD) 63 (12) 61 (11) 65 (7) .01
Age� 70 (%) 60 (28.6) 32 (21.8) 28 (46.6) .001
Male sex (%) 148 (70.5) 104 (70.7) 44 (69.8) .90
Organ transplant (%)
Kidney 108 (51.4) 74 (50.3) 34 (54.0) .63
Liver 50 (23.8) 37 (25.2) 13 (20.6) .48
Heart 33 (15.7) 24 (16.3) 9 (14.3) .71
Lung 15 (7.1) 9 (6.1) 6 (9.5) .56
Kidney-pancreas 4 (1.9) 3 (2.0) 1 (1.6) 1.00
Years from transplant to diagnosis, median (IQR) 6.6 (2.8–13.1) 7.1 (3.1–13.8) 5.5 (1.4–11.6) .048
Comorbidities (%)
Diabetes mellitusa 70 (33.3) 42 (28.6) 28 (44.4) .03
Chronic lung diseaseb 42 (20.0) 27 (18.4) 15 (23.8) .37
Chronic cardiopathyc 54 (25.7) 31 (21.1) 23 (36.5) .02
Chronic kidney diseased 74 (35.2) 46 (31.3) 28 (44.4) .07
Chronic liver diseasee 29 (13.8) 18 (12.2) 11 (17.5) .32
Cancerf 25 (11.9) 15 (10.2) 10 (15.9) .25
Morbid obesityg 10 (4.8) 9 (6.1) 1 (1.6) .16
Presenting symptoms (%)
Fever 140 (66.7) 101 (68.7) 39 (61.9) .34
Rhinorrhea 14 (6.7) 13 (8.8) 1 (1.6) .10
Odynophagia 16 (7.6) 10 (6.8) 6 (9.5) .69
Myalgias 54 (25.7) 42 (28.6) 12 (19.0) .15
Headache 18 (8.6) 16 (10.9) 2 (3.2) .07
Cough 137 (65.2) 94 (63.9) 43 (68.3) .55
Expectoration 34 (16.2) 23 (15.6) 11 (17.5) .74
Pleuritic chest pain 11 (5.2) 10 (6.8) 1 (1.6) .22
Dyspnea 81 (38.6) 44 (29.9) 37 (58.7) < .001
Diarrhea 81 (38.6) 59 (40.1) 22 (34.9) .48
Vomiting 20 (9.5) 14 (9.5) 6 (9.5) 1.00
Impaired consciousness 14 (6.7) 6 (4.1) 8 (12.7) .046
Days from symptoms onset to diagnosis, median (IQR) 6 (3–10) 6 (3–11) 5 (3–8) .64
Baseline immunosuppression (%)
Mofetil mycophenolate 145 (69.0) 101 (68.7) 44 (69.8) .87
Azathioprine 5 (2.4) 4 (2.7) 1 (1.6) 1.00
Ciclosporin 18 (8.6) 9 (6.1) 9 (14.6) .05
Tacrolimus 156 (74.3) 110 (74.8) 46 (73.0) .78
Sirolimus/everolimus 49 (23.3) 38 (25.9) 11 (17.5) .19
Prednisone 146 (69.5) 97 (66.0) 49 (77.8) .09
aTreated with insulin or antidiabetic oral drugs, or presence of end-organ diabetes-related disease.
bIncluding chronic obstructive pulmonary disease, obstructive sleep apnea, and asthma.
cIncluding cardiac insufficiency, coronary heart disease, aortic aneurysm, and peripheral arterial disease.
dMild (creatinine between 1.5–2 mg/dL) or moderate/severe (creatinine> 3 mg/dL or dialysis) renal impairment.
eMild (without portal hypertension) or moderate/severe (cirrhosis, varices, encephalopathy, ascites) liver disease.
fPresence of an active solid or hematologic malignant neoplasm.
gBody mass index� 40 kg/m2, or� 35 kg/m2 plus experiencing obesity-related health conditions.
https://doi.org/10.1371/journal.pone.0250796.t001
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counts, leukocytes were higher and lymphocytes lower in the unfavorable outcome group (P-
values, respectively, 0.04 and 0.03). By the same token, organ injury and inflammatory bio-
markers such as creatinine (P = 0.002), lactate dehydrogenase (P = 0.001), C-reactive protein
(P = 0.01), and D-dimer (P = 0.03) were higher among patients who later were admitted to the
ICU or died. These results and additional clinical details are available in Table 2.
Initial treatment approach, immunosuppression handling, and clinical
outcomes
Antiviral or host-targeted therapies were administered to 200 (95.2%) patients, with the most
used being hydroxychloroquine (193 (96.5%)), lopinavir/ritonavir (91 (45.5%)), and tocilizu-
mab (49 (24.5%)). Lopinavir/ritonavir (P = 0.003) and tocilizumab (P< 0.001) during hospi-
talization, as well as high flow therapy or mechanical ventilation (P< 0.001), were more
common practices towards severely ill patients (Table 3).
Immunosuppressive therapy was modified in 82.4% of cases, mainly by discontinuing
mofetil mycophenolate and reducing tacrolimus, while maintaining prednisone dosages. For
each agent, antimetabolite doses were decreased or stopped in 110/150 (73.3%) patients, calci-
neurin inhibitors in 119/170 (70.0%), and mTOR inhibitors in 35/49 (71.4%) patients. One
hundred thirty-three out of 146 (91.1%) patients had steroid doses maintained (Table 3).
Complications were more prevalent in the unfavorable outcome group compared to the
non-ICU or alive patients (P< 0.001). Twelve (5.7%) patients experienced graft dysfunction at
Fig 1. Age distribution of patients stratified by clinical outcome. Twenty-eight (46.6%) out of the 60 patients aged� 70 years experienced an
unfavorable outcome vs. 35 (23.3%) out of 150 patients aged< 70 years.
https://doi.org/10.1371/journal.pone.0250796.g001
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the end of follow-up, resulting in transplant loss for five patients (Table 3). Overall, 37 (17.6%)
SOTRs required ICU admission, and 45 (21.4%) died. A total of ten (4.8%) patients were dis-
charged and re-admitted during the study period.
Predictors of unfavorable outcomes
Unadjusted baseline predictors of unfavorable outcomes are shown in S2 Table. In the final
multivariable analysis, adjusted for gender, comorbidities, type of transplant, and doses of
immunosuppressive agents, four baseline risk factors were independently associated with
increased odds of ICU admission or death: age�70 years (P = 0.01), respiratory rate>20 bpm
Table 2. Initial chest x-ray imaging features, hemodynamic, and laboratory values in all patients and by clinical outcome at final follow-up in all patients and by
clinical outcome at final follow-up.
All (n = 210) Favorable Outcome (n = 147) Unfavorable Outcome (n = 63) P-value
Infiltrate on chest x-ray (%) 189 (90.0) 126 (85.7) 63 (100) .002
Signs (%)
Temperature > 37.5˚C 59 (28.6) 40 (27.6) 19 (31.1) .61
Systolic blood pressure< 90 mmHg 9 (4.5) 8 (5.7) 1 (1.6) .19
Diastolic blood pressure < 60 mmHg 20 (9.9) 13 (9.3) 7 (11.3) .66
Hart rate > 100 bpm 48 (25.1) 32 (24.4) 16 (26.7) .74
Respiratory rate > 20 bpm 57 (31.1) 27 (21.1) 30 (54.5) < .001
O2 sat < 95% 61 (29.2) 36 (24.7) 25 (39.7) .03
Blood counts, median (IQR)
White blood cells x 1000/μL 5.6 (4.0–7.8) 5.3 (3.8–7.5) 6.2 (4.4–8.2) .04
Neutrophils x 1000/μL 4.1 (2.9–5.9) 3.7 (2.8–5.6) 4.7 (3.1–6.8) .05
Lymphocytes x 1000/μL .8 (.5–1.0) .8 (.5–1.1) .6 (.4-.9) .03
Platelets x 1000/μL 164 (116–214) 158 (111–215) 173 (123–215) .26
Blood counts (%)
White blood cells > 11 x 1000/μL 16 (7.6) 8 (5.4) 8 (12.7) .13
Neutrophils > 7.5 x 1000/μL 25 (12.3) 14 (9.9) 11 (17.7) .12
Lymphocytes < 1 x 1000/μL 142 (68.6) 94 (64.4) 48 (78.7) .04
Platelets < 130 x 1000/μL 67 (33.0) 48 (33.8) 19 (31.1) .71
Chemistries, median (IQR)
Creatinine mg/dL 1.6 (1.1–2.3) 1.5 (1.0–2.2) 1.9 (1.3–2.4) .20
AST U/L 30 (22–44) 29 (21–42) 37 (26–52) .17
ALT U/L 23 (15–35) 21 (15–32) 27 (17–41) 1.00
Lactate dehydrogenase U/L 270 (223–366) 255 (207–323) 349 (255–484) .001
Chemistries (%)
Creatinine> 1.3 mg/dL 133 (63.9) 83 (57.2) 50 (79.4) .002
AST > 30 U/L 81 (49.7) 50 (45.5) 31 (58.5) .12
ALT > 40 U/L 37 (18.6) 22 (15.9) 15 (24.6) .15
Lactate dehydrogenase� 300 U/L 79 (40.9) 42 (31.6) 37 (61.7) < .001
Additional laboratory values, median (IQR)a
C-reactive protein mg/L 59.6 (26.9–127.2) 44.0 (20.6–112.6) 89.7 (47.3–133.9) .14
D-dimer ng/mL 612 (367–1399) 574 (340–1060) 799 (476–2315) .03
Additional laboratory values (%)a
C-reactive protein� 100 mg/L 69 (33.5) 40 (27.8) 29 (46.8) .01
D-dimer� 600 ng/mL 91 (52.3) 56 (47.9) 35 (61.4) .09
aThese values were not available for all patients (C-reactive protein N = 206, D-dimer N = 174).
https://doi.org/10.1371/journal.pone.0250796.t002
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(P = 0.001), lymphocytes <1 x 1000/μL (P = 0.04), and lactate dehydrogenase�300 U/L
(P = 0.04). A forest plot presenting the respective odds ratio and 95% confidence interval is
shown in Fig 2.
Among potential surrogates of immunosuppression intensity, we found a novel association
between unfavorable outcomes and the temporal proximity of COVID-19 to transplantation
(S3 Table). Through a series of sensitivity analyses, we further demonstrated the negative
impact of an earlier post-transplant infection on clinical prognosis (Table 4), as well as the lack
of association between the type of graft received and the occurrence of unfavorable outcomes
(S4 Table).
Two subgroups of the study population were considered of possible higher risk: patients
suffering from graft dysfunction at day 30, and those with COVID-19 acquisition during the
first month post-transplant. A detailed description of their main characteristics, outcomes,
and management is provided in S5 and S6 Tables.
Discussion
In this large, prospective, nationwide study of SOTRs hospitalized with COVID-19 followed
for 30 days, 17.6% required ICU admission, and the mortality rate was 21.4%. Older age, high
respiratory rate, lymphopenia, and elevated level of lactate dehydrogenase at presentation were
independently associated with ICU admission and/or death. Similarly, an earlier post-trans-
plant SARS-CoV-2 infection was demonstrated as a risk factor for unfavorable outcomes.
Table 3. Treatment and complications in all patients and by clinical outcome at final follow-up.
All (n = 210) Favorable Outcome (n = 147) Unfavorable Outcome (n = 63) P-value
Changes in immunosuppression (%)a
Decrease or stop antimetabolite 110/150 (73.3) 77/105 (73.3) 33/45 (73.3) 1.00
Decrease or stop calcineurin inhibitors 119/170 (70.0) 82/118 (69.5) 37/52 (71.2) .83
Decrease or stop mTOR inhibitors 35/49 (71.4) 26/38 (68.4) 9/11 (81.8) .63
Decrease or stop steroids 13/146 (8.9) 7/97 (7.2) 6/49 (12.2) .48
Viral or host-targeted medications (%)b
Hydroxychloroquine 193/200 (96.5) 134/140 (95.7) 59/60 (98.3) .61
Lopinavir/ritonavir 91/200 (45.5) 54/140 (38.6) 37/60 (61.7) .003
Darunavir/cobicistat 7/200 (3.5) 4/140 (2.9) 3/60 (5.0) .74
Interferon 6/200 (3.0) 2/140 (1.4) 4/60 (6.7) .12
Tocilizumab 49/200 (24.5) 23/140 (16.4) 26/60 (43.3) < .001
Azithromycin 34/200 (17.0) 28/140 (20.0) 6/60 (10.0) .09
Methylprednisolone 20/200 (10.0) 14/140 (10.0) 6/60 (10.0) 1.00
Highest level of respiratory support (%)
High flow/non-invasive mechanical ventilation 22 (10.5) 3 (2.0) 19 (30.2) < .001
Intubation 24 (11.4) 0 (0) 24 (38.1) < .001
Complications during hospitalization (%)
Acute respiratory distress syndrome 54 (26.0) 9 (6.2) 45 (72.6) < .001
Hospital-acquired coinfections 24 (11.9) 9 (6.3) 15 (25.9) < .001
Shock 15 (7.3) 0 (0) 15 (25.0) < .001
Graft dysfunction 12 (5.7) 9 (6.1) 3 (4.8) .95
Graft lost 5 (2.4) 3 (2.0) 2 (3.2) 1.00
aDenominator includes patients on the agent at baseline and known adjustment status.
bDenominator includes all patients under viral or host-targeted treatment.
https://doi.org/10.1371/journal.pone.0250796.t003
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The majority of patients were male with a median age over 60 years, conforming to prior
published large nationwide cohorts of the general population hospitalized with COVID-19
[32] and the 2019 Spanish National Transplant Organization Annual Report [33].
The potential negative impact of transplantation on clinical outcomes of COVID-19 has
been discussed, and the few authors that directly compared results in SOTRs and general pop-
ulation indicated that ICU admission and death rates were higher among the immunocompro-
mised hosts [34, 35]. However, studies including multivariable analyses of severity risk factors
among hospitalized general populations with COVID-19, though with variable durations of
follow-up, showed mortality and ICU admission estimates generally comparable to the ones
reported for the current SOTR cohort [36–39]. The presented fatality rate in our study was
also similar to the average of estimates derived from prior small and heterogeneous studies on
hospitalized SOTRs [10–12, 18, 30, 34] and just one percentage point higher than the single
previously published multicenter prospective SOTR cohort study (20.5%) [40]. By comparing
these incidence rates with those of clinical influenza for high-risk groups, we found close
resemblance in the probability of ICU admission (ranging from 11.8 to 28.6%) but less likeli-
hood of dying (between 2.9 and 14.3%) from flu among hospitalized patients [41–43], which
may be due to the existence of accessible and effective treatment.
Among the underlying comorbidities assessed, chronic cardiomyopathy, diabetes mellitus,
and chronic kidney disease were all present in more than one fourth of the patients included
and were associated with increased odds of unfavorable outcomes. This is in accordance with
the previously described comorbidities associated with ICU admission or death in the general
population [8, 36]. COVID-19 pneumonia at the time of diagnosis (defined by chest X-ray
infiltrates) was also associated with unfavorable outcomes, as reported in general population
studies [37, 38] and in the US multicenter SOTR cohort [40]. Moreover, no patients without
pneumonia in our cohort required ICU admission or died at final follow-up, solidifying pneu-
monia as a major determinant of unfavorable outcomes in SOTRs.
The most common presenting symptoms in our cohort included fever, cough, and dyspnea,
which were significantly associated with a poor clinical outcome. More atypical presentations,
such as vomiting or diarrhea, were also reported among a significant proportion of SOTRs.
This highlights that immunocompromised hosts often present with unusual or attenuated
Fig 2. Independent baseline predictors of unfavorable outcome.
https://doi.org/10.1371/journal.pone.0250796.g002
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Table 4. Baseline risk factors, management, and outcomes vs. time from transplantation to COVID-19 diagnosis.
All (n = 210) � 6 months from transplant to diagnosis
(n = 18)
> 6 months from transplant to diagnosis
(n = 192)
P-value
Baseline risk factors (%)
Age� 70 years 60 (28.6) 4 (22.2) 56 (29.2) .53
Diabetes mellitus 70 (33.3) 6 (33.3) 64 (33.3) 1.00
Chronic cardiopathy 54 (25.7) 5 (27.8) 49 (25.5) 1.00
Chronic kidney disease 74 (35.2) 5 (27.8) 69 (35.9) .49
Dyspnea 81 (38.6) 8 (44.4) 73 (38.0) .59
Respiratory rate > 20 bpm 57 (31.1) 7 (53.8) 50 (29.4) .13
O2 sat < 95% 61 (29.2) 6 (33.3) 55 (28.8) .69
Lymphocytes < 1 x 1000/μL 142 (68.6) 14 (77.8) 128 (67.7) .38
Creatinine> 1.3 mg/dL 133 (63.9) 12 (66.7) 121 (63.7) .80
Lactate dehydrogenase� 300 U/L 79 (40.9) 8 (50.0) 71 (40.1) .44
C-reactive protein� 100 mg/L 69 (33.5) 7 (41.2) 62 (32.8) .48
D-dimer� 600 ng/mL 91 (52.3) 12 (85.7) 79 (49.4) .05
Baseline immunosuppression (%)
Mofetil mycophenolate 145 (69.0) 15 (83.3) 130 (67.7) .17
Azathioprine 5 (2.4) 0 (0) 5 (2.6) 1.00
Ciclosporin 18 (8.6) 1 (5.6) 17 (8.9) 1.00
Tacrolimus 156 (74.3) 17 (94.4) 139 (72.4) .08
Sirolimus/everolimus 49 (23.3) 2 (11.1) 47 (24.5) .32
Prednisone 146 (69.5) 14 (77.8) 132 (68.8) .09
Changes in immunosuppression (%)a
Decrease or stop antimetabolite 110/150
(73.3)
8/15 (53.3) 102/135 (75.6) .12
Decrease or stop calcineurin inhibitors 119/170
(70.0)
9/17 (52.9) 110/153 (71.9) .11
Decrease or stop mTOR inhibitors 35/49 (71.4) 2/2 (100) 33/47 (70.2) .91
Decrease or stop steroids 13/146 (8.9) 2/14 (14.3) 11/132 (8.3) .80
Viral or host-targeted medications (%)b
Hydroxychloroquine 193/200
(96.5)
15/16 (93.8) 178/184 (96.7) 1.00
Lopinavir/ritonavir 91/200 (45.5) 6/16 (37.5) 85/184 (46.2) .50
Darunavir/cobicistat 7/200 (3.5) 1/16 (6.3) 6/184 (3.3) 1.00
Interferon 6/200 (3.0) 1/16 (6.3) 5/184 (2.7) .98
Tocilizumab 49/200 (24.5) 6/16 (37.5) 43/184 (23.4) .34
Azithromycin 34/200 (17.0) 0/16 (0) 34/184 (18.5) .11
Methylprednisolone 20/200 (10.0) 1/16 (6.3) 19/184 (10.3) .86
Highest level of respiratory support (%)
High flow/non-invasive mechanical
ventilation
22 (10.5) 3 (16.7) 19 (9.9) .62
Intubation 24 (11.4) 5 (27.8) 19 (9.9) .06
Complications during hospitalization (%)
Acute respiratory distress syndrome 54 (26.0) 7 (41.2) 47 (24.6) .23
Hospital-acquired coinfections 24 (11.9) 4 (25.0) 20 (10.8) .20
Graft dysfunction 12 (5.7) 2 (11.1) 10 (5.2) .62
Graft lost 5 (2.4) 1 (5.6) 4 (2.1) .91
Final outcome (%)
Intensive care unit admission 37 (17.6) 8 (44.4) 29 (15.1) .01
(Continued)
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signs and symptoms of infection, leading to late presentations or missed diagnosis, and poten-
tially worse results.
Among the inflammatory parameters measured at hospital admission, creatinine, lactate
dehydrogenase, C-reactive protein, and D-dimer levels were higher within the unfavorable
outcome group. However, the overall variation in these biomarkers was less pronounced than
that observed in the general population of hospitalized patients with COVID-19 [31, 44–46],
which is biologically plausible. This being the case, further investigation is required to address
whether the lower inflammatory response and greater immunosuppression characterizing
SOTRs have impacts on COVID-19 clinical outcomes.
The fundamental implication of our study is the identification of specific and independent
predictors (age�70 years, respiratory rate>20 bpm, lymphocytes <1 x 1000/μL, and lactate
dehydrogenase�300 U/L) for unfavorable outcomes in hospitalized SOTRs with COVID-19,
which could ease the development of future research and guidelines targeted at high-risk trans-
planted populations. Furthermore, we showed that an interval shorter than six months
between transplantation and COVID-19 diagnosis has a negative impact on mortality and
ICU admission rates, which is a risk that should be considered when deciding which patients
should proceed with transplantation. Finally, although analogous to the general population,
mortality in SOTRs hospitalized with SARS-CoV-2 infection is dramatically high, and the pro-
motion of preventive strategies and treatments will be crucial to mitigate the adverse impacts
of the COVID-19 pandemic in these patients.
The strengths of the present study are the strong design, the multicenter participation
approach to make the results generalizable and comparable, the standardized and anonymous
collection of data using an electronic Case Report Form, and the 30-day duration of follow-up.
In parallel, we have faced some limitations. First, our study is centered on hospitalized patients,
and thus the conclusions reached may not be applicable to those SOTRs attended in the outpa-
tient setting. Second, testing limitations probably led to undercounting of mild or asymptom-
atic cases, and the ensuing selection bias towards more severely ill patients. Finally, the cases
included only represent the early COVID-19 epidemic. Therefore, the potential benefit of ther-
apies that are now implemented more widely, such as remdesivir and convalescent plasma,
have not been addressed.
In summary, among hospitalized SOTR with COVID-19, ICU admission and death rates
were high, and they were similar to those reported in the general population. Unfavorable out-
comes were mainly driven by respiratory pathology (represented by a high breathing rate),
older age, and two laboratory features at presentation, namely lymphopenia and elevated level
of lactate dehydrogenase. An earlier post-transplant SARS-CoV-2 infection was established as
a novel risk factor for ICU need and mortality. While this study provides preliminary indica-
tors available upon hospital admission for identifying patients at risk of critical disease or
death, it is an urgent priority to find efficacious antiviral treatments and to investigate the role
Table 4. (Continued)
All (n = 210) � 6 months from transplant to diagnosis
(n = 18)
> 6 months from transplant to diagnosis
(n = 192)
P-value
Death 45 (21.4) 6 (33.3) 39 (20.3) .32
Unfavorable� 63 (30.0) 10 (55.6) 53 (27.6) .01
aDenominator includes patients on the agent at baseline and known adjustment status.
bDenominator includes all patients under viral or host-targeted treatment.
�Clinical outcome is categorized into favorable (full recovery and discharged or stable clinical condition) and unfavorable (admission to ICU or death).
https://doi.org/10.1371/journal.pone.0250796.t004
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of the immune response in COVID-19, especially in the population of SOTRs, where it is vital
to guide suitable and prompt immunomodulatory management.
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donado-Lizarazo, Ana Belén Martı́n-Gutiérrez, Rocı́o Valverde. Badajoz University Hospital,
Extremadura, Spain: Román Hernández-Gallego, Elena Garcı́a de Vinuesa-Calvo.
Author Contributions
Conceptualization: Jerónimo Pachón, Javier Sánchez-Céspedes, Elisa Cordero.
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Marino Blanes-Juliá, Elisa Vidal, Zaira R. Palacios-Baena, Román Hernández-Gallego,
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